These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24292099)

  • 21. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
    Horne KC; Howden BP; Grabsch EA; Graham M; Ward PB; Xie S; Mayall BC; Johnson PD; Grayson ML
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3447-52. PubMed ID: 19506056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of synergy between beta-lactams and anti-methicillin-resistant Staphylococcus aureus agents from the standpoint of strain characteristics and binding action.
    Ono D; Yamaguchi T; Hamada M; Sonoda S; Sato A; Aoki K; Kajiwara C; Kimura S; Fujisaki M; Tojo H; Sasaki M; Murakami H; Kato K; Ishii Y; Tateda K
    J Infect Chemother; 2019 Apr; 25(4):273-280. PubMed ID: 30713034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia.
    Takesue Y; Nakajima K; Takahashi Y; Ichiki K; Ishihara M; Wada Y; Tsuchida T; Uchino M; Ikeuchi H
    J Infect Chemother; 2011 Feb; 17(1):52-7. PubMed ID: 20625789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.
    Falcón R; Mateo E; Oltra R; Giménez E; Albert E; Torres I; Navarro D
    Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):903-912. PubMed ID: 30729396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.
    Jang HC; Kim SH; Kim KH; Kim CJ; Lee S; Song KH; Jeon JH; Park WB; Kim HB; Park SW; Kim NJ; Kim EC; Oh MD; Choe KW
    Clin Infect Dis; 2009 Aug; 49(3):395-401. PubMed ID: 19569970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of methicillin-resistant Staphylococcus aureus bacteremia and comparison of prognosis according to vancomycin MIC values: experience of the last ten years].
    Kızılarslanoğlu MC; Sancak B; Yağcı S; Hasçelik G; Unal S
    Mikrobiyol Bul; 2013 Apr; 47(2):199-210. PubMed ID: 23621720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.
    Barber KE; Rybak MJ; Sakoulas G
    J Antimicrob Chemother; 2015 Jan; 70(1):311-3. PubMed ID: 25125677
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
    Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
    Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonistic Effect of Colistin on Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus in
    Choi S; Moon SM; Park SJ; Lee SC; Jung KH; Sung HS; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS; Chong YP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp.
    Yoneda A; Thänert R; Burnham CD; Dantas G
    Int J Antimicrob Agents; 2020 Feb; 55(2):105864. PubMed ID: 31870598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Ribes S; Pachón-Ibáñez ME; Domínguez MA; Fernández R; Tubau F; Ariza J; Gudiol F; Cabellos C
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1361-7. PubMed ID: 20680368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.
    Welsh KJ; Abbott AN; Lewis EM; Gardiner JM; Kruzel MC; Lewis CT; Mohr JF; Wanger A; Armitige LY
    J Clin Microbiol; 2010 Mar; 48(3):894-9. PubMed ID: 20089758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of combined vancomycin and fosfomycin against methicillin-resistant Staphylococcus aureus in biofilms in vivo.
    Shi J; Mao NF; Wang L; Zhang HB; Chen Q; Liu H; Tang X; Jin T; Zhu CT; Li FB; Sun LH; Xu XM; Xu YQ
    PLoS One; 2014; 9(12):e113133. PubMed ID: 25551618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.
    McConeghy KW; Bleasdale SC; Rodvold KA
    Clin Infect Dis; 2013 Dec; 57(12):1760-5. PubMed ID: 23985343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters.
    Petraitis V; Petraitiene R; Kavaliauskas P; Naing E; Garcia A; Sutherland C; Kau AY; Goldner N; Bulow C; Nicolau DP; Walsh TJ
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0116821. PubMed ID: 34460301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA).
    Gould IM
    Int J Antimicrob Agents; 2013 Jun; 42 Suppl():S17-21. PubMed ID: 23664580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.
    Holubar M; Meng L; Deresinski S
    Infect Dis Clin North Am; 2016 Jun; 30(2):491-507. PubMed ID: 27208769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.
    Hagihara M; Wiskirchen DE; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):202-7. PubMed ID: 22006007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.